Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2023 | NIBIT-M2: 7-year outcomes and QoL analysis in melanoma patients

Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the seven-year efficacy outcomes and health-related quality-of-life (HRQoL) analyses of the Phase III NIBIT-M2 (NCT02460068) trial. The study evaluated the efficacy of fotemustine (Arm A) versus the combination of fotesmustine and ipilimumab (Arm B) or the combination of ipilimumab and nivolumab (Arm C) in patients with metastatic melanoma with brain metastasis. The seven-year overall survival (OS) rate was 10% in Arm A, 10.3% in Arm B, and 42.8% in Arm C. The seven-year intracranial progression-free survival (iPFS) rates were 4.3%, 7.7% and 28.6% in Arms A, B and C respectively. HRQoL was preserved in all treatment arm. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.